Information Provided By: 
Fly News Breaks for July 28, 2016
JAZZ
Jul 28, 2016 | 14:55 EDT
Wells Fargo analyst David Maris noted that U.S. Patent Office's Patent Trial and Appeal Board decided not to institute an inter partes review Jazz's 8,772,306 patent covering Xyrem, which he views as a strong positive for the durability of the franchise. Maris, who said the PTAB decision supports his belief that generic filers will face several significant challenges in their attempts to invalidate Xyrem's patent protection, keeps an Outperform rating on Jazz shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
